Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Prof. Irene Lang,
On Sunday evening (Meet the Experts session, Stockholm - Zone 4), a panel of five European experts in pulmonary hypertension challenged the new joint ERS/ESC Guidelines for pulmonary hypertension discussing treatment decisions in real-life cases.
Important contents of the current guidelines were reiterated. For example, in a Belgian case of a 77-year old gentleman with coronary disease presenting with newly manifest severe pulmonary arterial hypertension, the key observation of a “true” hemodynamic responder, i.e., an individual decreasing pulmonary arterial mean pressure by 10mmHg absolute, and below 40mmHg, in the absence of systemic hypotension, was discussed. While the patient fulfilled these criteria, the response was not maintained at 3 months, an observation which is generally to be expected in this age category, as was confirmed by Prof Sitbon (France) from the PH center in Clamart, France.
The second case of a young Italian woman with presumably hereditary pulmonary arterial hypertension raised the important question of first-line treatment for pulmonary arterial hypertension that is not specified in the current version of the new guidelines.
However, most importantly, these new guidelines are the first to introduce the concept of reassessing treatment goals after 3-6 months following introduction of a new treatment. Thus, in the case of both patients discussed in this session, rapid optimization of treatments was attained, despite the controversy about initial diagnostic and therapeutic steps.
“There will be amendments and free space for improvements” concluded the leading author of the guidelines, Prof Nazareno Galie, “but as our practice shows, we have been tailoring patient care according to the directions that are provided herein”.
How to manage pulmonary embolism and pulmonary hypertension in pregnancy?
© 2017 European Society of Cardiology. All rights reserved